16 October 2020: Original Paper
Expression of 6 Biomarkers in Liver Grafts After Pediatric Liver Transplantation: Correlations with Histology, Biochemistry, and Outcome
Sllja H. Voutilainen 1BCDEF , Silja K. Kosola 2BE* , Jouko Lohi 3BE , Aino Mutka 3BE , Timo Jahnukainen 4BE , Mikko Pakarinen 1AEG , Hannu Jalanko 4ACDEGDOI: 10.12659/AOT.925980
Ann Transplant 2020; 25:e925980
Table 3 Biomarker scores of the liver graft biopsies obtained at the first follow-up, patients divided in those with (n=13) and without (n=38) simultaneous inflammation. Data are presented as number of patients in each group (percentage). Some of the biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 3 histological areas. For this reason, the number of scored samples shows some variation between the different stainings.
| Patients without inflammation (n=38) | Patients with inflammation (n=13) | p-value | |
|---|---|---|---|
| α | |||
| Portal | 0.001 | ||
| 0 | 26 (77) | 3 (25) | |
| 1 | 7 (21) | 5 (42) | |
| 2 | 1 (3) | 4 (33) | |
| Lobular | 0.121 | ||
| 0 | 21 (62) | 4 (33) | |
| 1 | 6 (18) | 4 (33) | |
| 2 | 7 (21) | 4 (33) | |
| Central | 0.030 | ||
| 0 | 29 (85) | 7 (58) | |
| 1 | 5 (15) | 2 (17) | |
| 2 | 0 (0) | 3 (25) | |
| Portal | 0.025 | ||
| 0 | 26 (68) | 5 (42) | |
| 1 | 10 (26) | 3 (25) | |
| 2 | 1 (3) | 4 (33) | |
| Lobular | 0.551 | ||
| 0 | 31 (84) | 10 (77) | |
| 1 | 5 (14) | 2 (15) | |
| 2 | 1 (3) | 1 (8) | |
| Central | 0.251 | ||
| 0 | 29 (83) | 9 (69) | |
| 1 | 5 (13) | 2 (15) | |
| 2 | 1 (3) | 2 (15) | |
| Portal | 0.006 | ||
| 0 | 23 (74) | 3 (30) | |
| 1 | 7 (23) | 4 (40) | |
| 2 | 1 (3) | 3 (30) | |
| Lobular | 0.372 | ||
| 0 | 22 (71) | 6 (60) | |
| 1 | 8 (26) | 2 (20) | |
| 2 | 1 (3) | 2 (20) | |
| Central | 0.759 | ||
| 0 | 25 (83) | 8 (80) | |
| 1 | 4 (13) | 1 (10) | |
| 2 | 1 (3) | 1 (10) | |
| Portal | 0.014 | ||
| 0 | 15 (52) | 2 (17) | |
| 1 | 12 (41) | 6 (50) | |
| 2 | 2 (7) | 4 (33) | |
| Lobular | 0.116 | ||
| 0 | 18 (62) | 5 (42) | |
| 1 | 10 (35) | 4 (33) | |
| 2 | 1 (3) | 3 (25) | |
| Central | 0.114 | ||
| 0 | 28 (97) | 10 (83) | |
| 1 | 0 (0) | 0 (0) | |
| 2 | 1 (3) | 2 (17) | |
| Portal | 0.014 | ||
| 0 | 18 (67) | 3 (30) | |
| 1 | 8 (30) | 3 (30) | |
| 2 | 1 (4) | 4 (40) | |
| Lobular | 0.061 | ||
| 0 | 25 (93) | 7 (70) | |
| 1 | 2 (7) | 1 (10) | |
| 2 | 0 (0) | 2 (20) | |
| Central | 0.100 | ||
| 0 | 27 (100) | 9 (90) | |
| 1 | 0 (0) | 0 (0) | |
| 2 | 0 (0) | 1 (10) | |
| Portal | 0.052 | ||
| 0 | 31 (86) | 7 (58) | |
| 1 | 4 (11) | 5 (42) | |
| 2 | 1 (3) | 0 (0) | |
| Central | 0.007 | ||
| 0 | 28 (80) | 5 (39) | |
| 1 | 6 (17) | 7 (54) | |
| 2 | 1 (3) | 1 (8) | |
| α-SMA – α-smooth muscle actin; PSGL-1 – P-selectin glycoprotein ligand-1. * p-value for the significance of the difference in the distribution of biomarker scores between patients without and with inflammation calculated with Kruskal-Wallis test. | |||